The estimated Net Worth of Richard William Scalzo is at least $10.8 Million dollars as of 11 September 2024. Mr Scalzo owns over 1,468 units of Dyne Therapeutics stock worth over $3,258,631 and over the last 4 years he sold DYN stock worth over $7,565,972.
Mr has made over 20 trades of the Dyne Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,468 units of DYN stock worth $46,815 on 11 September 2024.
The largest trade he's ever made was selling 126,074 units of Dyne Therapeutics stock on 6 September 2024 worth over $4,053,279. On average, Mr trades about 11,747 units every 39 days since 2020. As of 11 September 2024 he still owns at least 99,958 units of Dyne Therapeutics stock.
You can see the complete history of Mr Scalzo stock trades at the bottom of the page.
Richard Scalzo is the VP of Accounting & Admin. and Treasurer at Dyne Therapeutics.
Mr Scalzo is 33, he's been the VP of Accounting & Admin. and Treasurer of Dyne Therapeutics since . There are 25 older and no younger executives at Dyne Therapeutics. The oldest executive at Dyne Therapeutics, Inc. is Yuezhou Ou, 68, who is the Independent Non-Executive Director.
Richard's mailing address filed with the SEC is C/O DYNE THERAPEUTICS, INC., 1560 TRAPELO ROAD, WALTHAM, MA, 02451.
Over the last 4 years, insiders at Dyne Therapeutics have traded over $197,573,300 worth of Dyne Therapeutics stock and bought 5,790,447 units worth $92,382,301 . The most active insiders traders include Capital Management, L.P.Kol..., Jason P Rhodes, and Dirk Kersten. On average, Dyne Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of $3,566,016. The most recent stock trade was executed by Oxana Beskrovnaya on 11 September 2024, trading 2,161 units of DYN stock currently worth $68,914.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Dyne Therapeutics executives and other stock owners filed with the SEC include: